NCT00139269已完成1 期
Phase I/II Pilot Study of Induction Chemotherapy With Docetaxel in Combination With Cisplatin and 5-Fluorouracil (5-FU) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
- 主要终点
- To determine whether cisplatin in combination with docetaxel and 5-fluorouracil can be given with acceptable side effects
研究概览
简要总结
The purpose of this study is to determine the appropriate dose, that dose which is found to give maximum effect with limited toxicity, of cisplatin in combination with docetaxel and 5-fluorouracil and then to further define the safety and effectiveness of this combination of medications.
详细描述
- Treatment begins with a one hour infusion of docetaxel followed by a 1/2 hour infusion of cisplatin. 5-fluorouracil will be administered through continuous IV infusion through a portable pump for four days at home. A cycle is twenty-one days long ( 4 days of chemotherapy and 17 days of recovery).
- During each cycle blood tests will be performed weekly. A physical exam will be performed and the impact of the chemotherapy will be assessed at the end of each cycle.
- If after 2 cycles the patients cancer has not responded sufficiently they will be removed from the study.
- If significant reduction in the size of the tumor is observed after cycle 2, a third and final cycle will be performed. Followed by radiation therapy twice daily for approximately 6-7 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of head and neck (SSCHN).
- •At least one bi- or uni-dimensionally measurable lesion.
- •Stage II or IV disease without evidence of distant metastasis.
- •No previous chemotherapy, radiotherapy or surgery (other than biopsy) for SSCHN.
- •Age greater than 18 years.
- •ECOG performance status of 0 or
- •Life expectancy of greater than 12 weeks.
- •Adequate bone marrow, hepatic and renal function.
- •Normal serum calcium
排除标准
- •Primary tumor location in nasopharynx, nasal cavity, sinuses, or salivary glands.
- •Patients with any non-SSCHN malignancy within 5 years of study entry, except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix.
- •Any prior treatment with chemotherapy.
- •Prior radiotherapy to major bone marrow area (> 10% bone marrow) or to head and neck.
- •Current peripheral neuropathy of greater than NCI grade
- •Other serious illness or medical condition
- •Concurrent treatment with corticosteroids unless chronic treatment at low doses.
- •Pregnant or lactating females or females of childbearing potential not employing adequate contraception.
结局指标
主要结局
To determine whether cisplatin in combination with docetaxel and 5-fluorouracil can be given with acceptable side effects
to determine the efficacy of said combination.
次要结局
- To define the safety profile, the dose limiting toxicity and the recommended dose of cisplatin in combination with docetaxel and 5-fluorouracil.
研究者
相似试验
Unknown
1 期
Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)Esophageal CancerNCT00915850Wakayama Medical University32
已完成
2 期
Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)Nasopharyngeal CarcinomaNCT01326559Hong Kong Nasopharyngeal Cancer Study Group Limited33
终止
1 期
IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaMelanomaNCT01409174M.D. Anderson Cancer Center19
已完成
1 期
Phase I Trial of BAY1251152 for Advanced Blood CancersHematologic NeoplasmsNCT02745743Bayer21
招募中
1 期
IKS014 in Advanced Solid Tumors That Express HER2Gastroesophageal-junction CancerBreast CancerGastric CancerNCT05872295Iksuda Therapeutics Ltd.165